Top 31-35
09 June 2011 | News
 |
DiagnoSearch Life Sciences |
DiagnoSearch
Life
Sciences, formerly iGate Clinical Research, recorded revenues of
 121 crore for 2010-11 as against previous
year’s revenue of 97 crore.
DiagnoSearch has passed over 100 CQA audits by North American and
European biopharmaceutical companies and offers a complete range of
phase I to IV clinical trials support services. Over the past 12 years,
DiagnoSearch managed over 100 clinical trials for global sponsors in a
broad range of therapeutic areas. The company has a headcount of more
than 100 staff and is going to come up with a new 30,000 sq ft office
facility. The firms mainly operates using three divisions, namely,
clinical operations, monitoring and the project management division.
The firm has a central laboratory that offers comprehensive solutions
including, production of bar-coded, visit-specific kits, investigator
team training, state-of-the-art analytical methods, efficient specimen
shipment and automated data reporting. |
| Founder
and MD Dr Vasudeo Ginde |
||
|
31
|
Business: Offering a complete range clinical trials support services | |
| Start-up Year: 1975 | ||
| Address:
101, First Floor, B G House, Orchard Avenue, Hiranandani, Business
Park, Mumbai-400076 |
||
| Tel: +91-22-66976300 Fax: +91-22-66754090 Website: www.diagnosearch.com |
||
| Revenue: 121
crore* |
||
 |
Veeda Clinical Research |
Veeda
Clinical
Research, is a full service global CRO specializing in early
clinical development of drugs (phase I and IIa) with state-of-the-art
facilities in the UK, India and Belgium. It recorded revenues of 120
crore during the FY 2010-11 as against last year’s revenue of 112
crore, with a growth of about 7.14 percent. Veeda has been growing at a
rate of 70 percent since its inception and aims to achieve a turnover
of 325 crore in the next three years. The
firm has acquired four CROs
in Europe and presently houses state-of-the-art phase I facilities in
Plymouth, UK; Ahmedabad, India and Görlitz, Germany. In October
2010, Veeda announced the opening of its facility at Ahmedabad, spread
across three floors with an area of 25,000 sq ft. In May 2011, Veeda
announced that the final steps have been put in place for the
commissioning of its CRC Veeda (Malaysia) phase I unit in the Ampang
Hospital in Kuala Lumpur, Malaysia. |
| Founders
& MDs Mr Apurva Shah & Mr Binoy Gardi |
||
|
32
|
Business: Specializes in early clinical development | |
| Start-up
Year: 2005 |
||
| Address: Veeda Clinical Research –
India, Shivalik Plaza-A, Near IIM, Ambawadi, Ahmedabad- 380015 |
||
| Tel: +91-79-30013000 Fax: +91-79-30013010 Website: www.veedacr.com |
||
| Revenue: 120
crore |
||
 |
Intas Biopharmaceutical |
Intas
Biopharmaceutical
(IBPL) clocked revenue of 110 crore in FY 2010-11 as
compared to 115 crore in the previous FY. Intas
Pharmaceuticals,
IBPL’s parent compnay has filed its red herring prospectus (DRHP) with
SEBI and is looking to raise 425 crore. The firm has presently
developed and commercialized five products in India and other
semi-regulated markets in Africa, Latin America and Asia Pacific and
has an additional 11 projects at advanced stages of development, out of
which, nine projects are for the Indian market and two are for
regulated markets. IBPL also intends to invest 15.33 crore at the
Moraiya facility. The company launched bortezomib injection, under the brand name Borviz, which is expected to offer an effective treatment for multiple myeloma. The company will also invest 160 crore towards
setting up a manufacturing facility at Sanand, near Ahmedabad, to
produce monoclonal antibodies with a capacity of 5,000 liter in phases. |
| CEO
(MD) Dr Urmish Chudgar |
||
|
33
|
Business: R&D, manufacturing & marketing of recombinant products and oncology drugs | |
| Start-up
Year: 2006 |
||
| Address:
Plot No 423/P/A/GIDC, Moraiya, Sarkhej-Bavla highway, Tal: Sanand,
Ahmedabad-382210 |
||
| Tel: +91-2717-660101 Fax: +91-2717-251189 Website: www.intasbiopharma.co.in |
||
| Revenue: 110
crore* |
||
 |
Diagnova (A division of RFCL) |
Diagnova
is
the diagnostic division of RFCL, which is now part of US-based
Avantor Performance Materials. In FY 2010-11, Diagnova recorded a
sluggish growth with revenues of 103 crore as compared to 100 crore
in the FY 2009-10. This firm’s manufacturing plant is situated in
Dehradun, Uttarakhand, and the company offers quality products and
services to over 6,000 customers. The business of Diagnova is divided
into three strategic units: In Vitro Diagnostics (IVD), Medical
Sciences Group (MSG) and Life Sciences Group (LSG). Diagnova has an ISO
certified manufacturing setup for IVD products based at Haridwar,
Uttaranchal. The MSG Group of Diagnova markets medical devices in the
field of gastroenterology with a product profile that covers ph &
motility systems, breath test analyzer, cardiac surveyor and surgical
staplers among others. The LSG group offers solutions for the molecular
biology segment and emerging areas like protein crystallography &
drug discovery. |
| MD Mr Sushil Mehta |
||
|
34
|
Business: Diagnostics | |
| Start-up
Year: 2005 |
||
| Address: A-3, Okhla Industrial Area
Phase-I, New Delhi-110 020 |
||
| Tel: +91-11-42395700 Fax: +91-11-41609189 Website: www.rfcl.in/dignova, www.diagnova.in |
||
| Revenue: 103
crore |
||
 |
Vimta Labs |
Vimta
Labs,
one of India’s leading contract research and testing
organization, reported a revenue of 96.5 crore in FY 2010-11 as
compared to 88.42 crore in 2009-10. The company employs 756 personnel, including 479 scientists, and boasts of more than 300,000 sq ft of world class laboratory facilities. Vimta Labs achieved AAALAC International full accreditation in February, 2011, and the company conducts its operations in compliance with ICH-GCP and GLP. The company has a large bioanalytical group, equipped with 26 mass spectrometers across two sites, operational round the clock. Over 200 bioanalytical methods have been developed and validated at Vimta Labs and the firm conducted over 1,100 BA/BE studies on various dosage forms such as tablets, capsules, extended release preparations, gels, jelly’s, solutions, transdermal patches and injectibles among others. |
| CMD Dr S P Vasireddi |
||
|
35
|
Business: Contract research | |
| Start-up Year: 1984 | ||
| Address: 142, IDA,Phase II,
Cherlapally, Hyderabad-500 051 |
||
| Tel: +91-40-27264141 Fax: +91-40-27263657 Website: www.vimta.com |
||
| Revenue: 96.5
crore |
||
